8 April 2016 - The Department of Health has asked NICE to produce guidance on the use of azacitidine in the NHS in England.

The NICE Appraisal Committee has considered the evidence submitted by the company and the views of non-company consultees and commentators, clinical experts and patient experts.

Azacitidine is not recommended, within its marketing authorisation, for treating acute myeloid leukaemia with more than 30% bone marrow blasts in people of 65 years or older who are not eligible for haematopoietic stem cell transplant.

NICE invites comments from the consultees and commentators for this appraisal (see section 8) and the public.

After considering comments, the committee will prepare the a FAD.

The anticipated publication date of the FAD is 27 July 2016.

For more details, go to: https://www.nice.org.uk/guidance/indevelopment/GID-TA10000/consultation/html-content

To see the entries for azacitidine in the MAESTrO database, click here: https://app.maestrodatabase.com/app/reimbursement/browse/technology/azacitidine